DrugPatentWatch Database Preview
Eagle Pharms Company Profile
» See Plans and Pricing
What is the competitive landscape for EAGLE PHARMS, and when can generic versions of EAGLE PHARMS drugs launch?
EAGLE PHARMS has five approved drugs.
There are twenty-four US patents protecting EAGLE PHARMS drugs. There is one tentative approval on EAGLE PHARMS drugs.
There are one hundred and thirteen patent family members on EAGLE PHARMS drugs in thirty-three countries and two supplementary protection certificates in two countries.
Summary for Eagle Pharms
| International Patents: | 113 |
| US Patents: | 24 |
| Tradenames: | 5 |
| Ingredients: | 4 |
| NDAs: | 5 |
Drugs and US Patents for Eagle Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eagle Pharms | BENDEKA | bendamustine hydrochloride | SOLUTION;IV (INFUSION) | 208194-001 | Dec 7, 2015 | RX | Yes | Yes | 9,572,887 | Start Trial | Start Trial | ||||
| Eagle Pharms | BENDEKA | bendamustine hydrochloride | SOLUTION;IV (INFUSION) | 208194-001 | Dec 7, 2015 | RX | Yes | Yes | 9,597,398 | Start Trial | Start Trial | ||||
| Eagle Pharms | BENDEKA | bendamustine hydrochloride | SOLUTION;IV (INFUSION) | 208194-001 | Dec 7, 2015 | RX | Yes | Yes | 9,034,908 | Start Trial | Start Trial | ||||
| Eagle Pharms | BENDEKA | bendamustine hydrochloride | SOLUTION;IV (INFUSION) | 208194-001 | Dec 7, 2015 | RX | Yes | Yes | 9,265,831 | Start Trial | Y | Start Trial | |||
| Eagle Pharms | BENDEKA | bendamustine hydrochloride | SOLUTION;IV (INFUSION) | 208194-001 | Dec 7, 2015 | RX | Yes | Yes | 9,000,021 | Start Trial | Start Trial | ||||
| Eagle Pharms | RYANODEX | dantrolene sodium | FOR SUSPENSION;INTRAVENOUS | 205579-001 | Jul 22, 2014 | RX | Yes | Yes | 8,110,225 | Start Trial | Y | Start Trial | |||
| Eagle Pharms | ARGATROBAN IN SODIUM CHLORIDE | argatroban | INJECTABLE;INTRAVENOUS | 022434-001 | Jun 29, 2011 | RX | Yes | Yes | 7,687,516 | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for EAGLE PHARMS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Injection | 100 mg/4 mL (25 mg/mL) multiple-dose vials | ➤ Subscribe | 2017-05-04 |
International Patents for Eagle Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Slovenia | 2528602 | Start Trial |
| Poland | 2827863 | Start Trial |
| Israel | 251405 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2013142359 | Start Trial |
| Denmark | 2827863 | Start Trial |
| Japan | 2013518130 | Start Trial |
| Hong Kong | 1243346 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Eagle Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0432677 | SPC/GB05/011 | United Kingdom | Start Trial | PRODUCT NAME: PEMETREXED AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/04/290/001 20040920 |
| 0432677 | 7/2005 | Austria | Start Trial | PRODUCT NAME: PEMETREXED UND DESSEN PHARMAZEUTISCH ANNAHMBAREN SALZE; REGISTRATION NO/DATE: EU/1/04/290/001 20040920 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
